Search

Displaying results 1031 - 1040 of 5449 in total
  1. Drug

    Cantharidin

    go.drugbank.com/drugs/DB12328
    ApprovedInvestigational

    [A32891, A32892] Topical cantharidin products do not necessarily demonstrate any particular better effectiveness at treating topical skin conditions like warts than other commonly available vesicant … [A32892] Nevertheless, it gained its first FDA approval on Jul 21, 2023, under the brand name YCANTH™ by Verrica Pharmaceuticals for the treatment of molluscum contagiosum in adult and pediatric patients

  2. Drug

    Birch bark extract

    go.drugbank.com/drugs/DB16536
    ApprovedInvestigational

    Some of the compounds identified in it include betulin, [lupeol], [betulinic acid], oleanolic acid, and erythrodiol. … [L42365,L42370] Filsuvez, one of these two formulations, is approved for the treatment of partial thickness wounds in patients with epidermolysis bullosa (EB), a rare group of hereditary disorders of the

  3. Drug

    Collagenase clostridium histolyticum

    go.drugbank.com/drugs/DB00048
    ApprovedInvestigational

    It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease.

  4. Drug

    Eucalyptus oil

    go.drugbank.com/drugs/DB11114
    Approved

    It is also shown to exhibit antibacterial activity against some bacterial species and cough suppressant actions. … It is shown to be effective in reducing pain, swelling, and inflammation via its modulatory effect on the immune response.

    Mixtures: ST. LUKE`S SPORTS OIL, DT Vaporizing Chest Rub
  5. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    [L39665,L39680] It is the first IL-17 inhibitor to target both IL-17A and IL-17F. … Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis.

  6. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    [L41265,L41300] It was the first anti-LAG-3 antibody to demonstrate benefit in a Phase 3 study, as well as the first to receive FDA approval. … [A246165,L41265] It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013,[A246155] and has garnered interest in the treatment of a variety of cancers, including leukemia

  7. Drug

    Esmolol

    go.drugbank.com/drugs/DB00187
    ApprovedInvestigationalWithdrawn

    It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. … It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions.

    Products: ESOCARD INJECTION 10 MG / ML, Esmolol Hikma 10 mg/ml Injektionslösung
  8. Drug

    Acemetacin

    go.drugbank.com/drugs/DB13783
    ApprovedInvestigational

    [T50] It was developed by E. … It is a potent non-steroidal anti-inflammatory drug, derived from the indol-3-acetic acid, whose activity is thought to be mainly through its active metabolite indomethacin.

    Products: ACEMETACIN - CT 30MG HARTK, ACEMETACIN - CT 60MG HARTK
  9. Drug

    Fondaparinux

    go.drugbank.com/drugs/DB00569
    ApprovedInvestigational

    infarction (NSTEMI); and in the management of ST segment elevation myocardial infarction (STEMI). … It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units.

    Products: ARIXTRA (12.5 MG/ML), ARIXTRA 2.5 MG / 0.5 ML
  10. Drug

    Nitric Oxide

    go.drugbank.com/drugs/DB00435
    ApprovedInvestigational

    It is also a toxic air pollutant produced by automobile engines and power plants. … It reacts with the ozone in air to form nitrogen dioxide, signalled by the appearance of the reddish-brown color.

    Products: NOW st, NOtatione Pet care (Helps improve metabolic disorder, Cabbage fermented powder)